Principal Research Scientist, Head-High Throughput Chemistry Group, USA
The speed and efficiency of small molecule candidate discovery relies heavily on hit identification and lead optimization through structure-activity relationship studies. The ability to generate novel bioactive analogs fast and effectively is of utter importance for any medicinal chemistry program. In this context, the high throughput chemistry (HTC) group at AbbVie utilizes multiple industry-leading enabling chemistry technologies that have been developed and implemented to deliver impact on many drug discovery programs across AbbVie. In this presentation, we will present recent developments in HTC to enable the efficient and fast delivery of crucial intermediates and bioactive compounds, with a specific focus on application of parallel synthesis and platforms, flow chemistry and high throughput experimentation technologies in drug discovery.